Keryx Biopharma - KERX

Aeiou ha scritto:
:eek: fai kukù e vai con le minorenni? :eek: :D Ma chi ti credi di essere!? :lol:
Clicca per allargare...

:cool::cool::cool: :D:D:D:lol::lol:

mi consenta............ :D

040817_Berlusconi_vmed_11a.widec.jpg
 
CC & Perifosine ASCO Data
A brief summary on the conference call this morning. James Oliverio (CFO) and Michael Tarnok (Interim CEO and Board member) updated shareholders on KERX's financial condition and clinical progress. Here are a few of the highlights that were not mentioned in the press release:

- Due to a decrease in R&D spending on Selenex, the company turned a profit. R&D spending continued on Zerenex and Perifosine.
- Company currently has 15.4M in cash as well as 7.1M in auction rate securities (fair value of $10M).
- Oliverio stated that the company intends to hold onto the auction rate securities until liquidity conditions improve. Stated that KERX would not need to tap into these funds until early 2010.
- Plan to choose 1 of the 2 late stage products to take forward to Phase III. This will increase the cash burn rate to $1M/month.
- This plan will allow company to stay solvent through Q1 2010 (strongly suggests to me that KERX will partner Perifosine to raise cash).
- Tarnok is leading the search for a new CEO. To date, they have identified a number of strong candidates and hope to have an announcement shortly.

PERIFOSINE

- Perifosine data has been selected by ASCO for several oral and poster presentations at this month's meeting.
- Data will be available tonight at http://www.asco.org beginning at 6 PM
- Data on kidney, collorectal cancer, and GIST (gastrointestinal stromal tumors) to be presented.
- This brings the number of cancer targets to 4, including previous data in multiple myeloma.
- Data at ASCO will feature both single agent efficacy as well as the ability to combine Perifosine with other active cancer agents.
- Perifosine data was presented at International Myeloma Foundation meeting last month. Continue to show strong efficacy - and supports moving forward to Phase III in MM.
- Two biggest investigators in MM, Paul Richardson and Ken Anderson, have agreed to help write the Phase III protocol for Perifosine to enable an approval.
- Tarnok mentioned that KERX plans to have active discussions with the FDA to agree on a path to approval for Perifosine - as well as Zerenex.
- Tarnok said KERX is "considering all options" as it relates to developing 1 of their 2 late stage products. This would include bringing a product to market on their own OR licensing the product to another company to raise cash and share in the development costs.

This is some amazing and exciting news. Perifosine is a clear winner in multiple myeloma (MM) - with the potential to be a $500M product in this indication alone. If the product works in colon, kidney, and GIST, Perifosine is a billion dollar cancer drug (a short list of products can currently make that claim today).
 
acqua+ ha scritto:
CC & Perifosine ASCO Data
A brief summary on the conference call this morning. James Oliverio (CFO) and Michael Tarnok (Interim CEO and Board member) updated shareholders on KERX's financial condition and clinical progress. Here are a few of the highlights that were not mentioned in the press release:

- Due to a decrease in R&D spending on Selenex, the company turned a profit. R&D spending continued on Zerenex and Perifosine.
- Company currently has 15.4M in cash as well as 7.1M in auction rate securities (fair value of $10M).
- Oliverio stated that the company intends to hold onto the auction rate securities until liquidity conditions improve. Stated that KERX would not need to tap into these funds until early 2010.
- Plan to choose 1 of the 2 late stage products to take forward to Phase III. This will increase the cash burn rate to $1M/month.
- This plan will allow company to stay solvent through Q1 2010 (strongly suggests to me that KERX will partner Perifosine to raise cash).
- Tarnok is leading the search for a new CEO. To date, they have identified a number of strong candidates and hope to have an announcement shortly.

PERIFOSINE

- Perifosine data has been selected by ASCO for several oral and poster presentations at this month's meeting.
- Data will be available tonight at http://www.asco.org beginning at 6 PM
- Data on kidney, collorectal cancer, and GIST (gastrointestinal stromal tumors) to be presented.
- This brings the number of cancer targets to 4, including previous data in multiple myeloma.
- Data at ASCO will feature both single agent efficacy as well as the ability to combine Perifosine with other active cancer agents.
- Perifosine data was presented at International Myeloma Foundation meeting last month. Continue to show strong efficacy - and supports moving forward to Phase III in MM.
- Two biggest investigators in MM, Paul Richardson and Ken Anderson, have agreed to help write the Phase III protocol for Perifosine to enable an approval.
- Tarnok mentioned that KERX plans to have active discussions with the FDA to agree on a path to approval for Perifosine - as well as Zerenex.
- Tarnok said KERX is "considering all options" as it relates to developing 1 of their 2 late stage products. This would include bringing a product to market on their own OR licensing the product to another company to raise cash and share in the development costs.

This is some amazing and exciting news. Perifosine is a clear winner in multiple myeloma (MM) - with the potential to be a $500M product in this indication alone. If the product works in colon, kidney, and GIST, Perifosine is a billion dollar cancer drug (a short list of products can currently make that claim today).
Clicca per allargare...

:sorpresa::sorpresa::sorpresa::sorpresa::sorpresa:
:D
5$ please-------------- :D
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 1 (members: 0, guests: 1)
Back
Alto